Corrigendum: A whole-cell tumor vaccine modified to express fibroblast activation protein induces antitumor immunity against both tumor cells and cancer-associated fibroblasts (Scientific Reports (2015) 5 (14421) DOI: 10.1038/srep14421);A whole-cell tumor vaccine modified to express fibroblast activation protein induces antitumor immunity against both tumor cells and cancer-associated fibroblasts

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Chen, Meihua ^a   Xiang, Rong ^b   Wen, Yuan ^a   Xu, Guangchao ^a   Wang, Chunting ^a   Luo, Shuntao ^a   Yin, Tao ^a   Wei, Xiawei ^a   Shao, Bin ^a   Liu, Ning ^a   Guo, Fuchun ^a   Li, Meng ^a   Zhang, Shuang ^a   Li, Minmin ^a   Ren, Kexing ^a   Wang, Yongsheng ^a   Wei, Yuquan ^a  

^a SICHUAN UNIVERSITY   (China)

^b NANKAI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; GELATINASE; MEMBRANE PROTEIN; SEPRASE; SERINE PROTEINASE; TUMOR ANTIGEN;

ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; CARCINOMA, LEWIS LUNG; CD8+ T LYMPHOCYTE; COLONIC NEOPLASMS; FIBROBLAST; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MELANOMA, EXPERIMENTAL; MOUSE; PROCEDURES; TUMOR CELL LINE; TUMOR MICROENVIRONMENT; VACCINATION;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CARCINOMA, LEWIS LUNG; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; COLONIC NEOPLASMS; FIBROBLASTS; GELATINASES; IMMUNOTHERAPY; MELANOMA, EXPERIMENTAL; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; SERINE ENDOPEPTIDASES; TUMOR MICROENVIRONMENT; VACCINATION;

EID: 84942163616     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep46841     Document Type: Erratum

References (51)

1. Cheng, J. D. & Weiner, L. M. Tumors and their microenvironments: tilling the soil. Commentary re: A. M. Scott et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res., 9: 1639-1647, 20. Clin. Cancer Res. 9, 1590-1595 (2003).
2. Cirri, P. & Chiarugi, P. Cancer associated fibroblasts: the dark side of the coin. Am. J. Cancer Res. 1, 482-497 (2011).
3. Franco, O. E., Shaw, A. K., Strand, D. W. & Hayward, S. W. Cancer associated fibroblasts in cancer pathogenesis. Semin. Cell Dev. Biol. 21, 33-39, doi: 10.1016/j.semcdb.2009.10.010 (2010).
4. Mellman, I., Coukos, G. & Dranoff, G. Cancer immunotherapy comes of age. Nature 480, 480-489, doi: 10.1038/nature10673 (2011).
5. Orimo, A. & Weinberg, R. A. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 5, 1597-1601, doi: 3112 (2006).
6. Wu, J. & Deng, H. [Interaction of cancer-associated fibroblasts and tumor cells in carcinogenesis]. Zhejiang Da Xue Xue Bao Yi Xue Ban 37, 212-217 (2008).
7. Copier, J. & Dalgleish, A. Overview of tumor cell-based vaccines. Int. Rev. Immunol. 25, 297-319, doi: 10.1080/08830180600992472 (2006).
8. de Gruijl, T. D., van den Eertwegh, A. J., Pinedo, H. M. & Scheper, R. J. Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunol. Immunother. 57, 1569-1577, doi: 10.1007/s00262-008- 0536-z (2008).
9. Chiang, C. L., Benencia, F. & Coukos, G. Whole tumor antigen vaccines. Semin. Immunol. 22, 132-143, doi: 10.1016/j. smim.2010.02.004 (2010).
10. Kudrin, A. & Hanna, M. G., Jr. Overview of the cancer vaccine field: are we moving forward? Hum. Vaccin. Immunother. 8, 1135-1140, doi: 10.4161/hv.20474 (2012).
11. Chiang, C. L., Kandalaft, L. E. & Coukos, G. Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines. Int. Rev. Immunol. 30, 150-182, doi: 10.3109/08830185.2011.572210 (2011).
12. Zajac, A. J. et al. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188, 2205-2213 (1998).
13. Copier, J. & Dalgleish, A. Whole-cell vaccines: A failure or a success waiting to happen? Curr. Opin. Mol. Ther. 12, 14-20 (2010).
14. Willimsky, G. et al. Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J. Exp. Med. 205, 1687-1700, doi: 10.1084/jem.20072016 (2008).
15. Speiser, D. E. et al. A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination. J. Immunol. 177, 1338-1348 (2006).
16. Kraman, M. et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 330, 827-830, doi: 10.1126/science.1195300 (2010).
17. Comes, A. et al. CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. J. Immunol. 176, 1750-1758 (2006).
18. Oniki, S. et al. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res. 66, 6395-6404, doi: 10.1158/0008-5472.CAN-05-4087 (2006).
19. Loeffler, M., Kruger, J. A., Niethammer, A. G. & Reisfeld, R. A. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J. Clin. Invest. 116, 1955-1962, doi: 10.1172/JCI26532 (2006).
20. Ghirelli, C. & Hagemann, T. Targeting immunosuppression for cancer therapy. J. Clin. Invest. 123, 2355-2357, doi: 10.1172/ jci69999 (2013).
21. Garin-Chesa, P., Old, L. J. & Rettig, W. J. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc. Natl. Acad. Sci. USA 87, 7235-7239 (1990).
22. Rettig, W. J. et al. Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res. 53, 3327-3335 (1993).
23. Loeffler, M. et al. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. [Erratum appears in J Clin Invest. 2009 Feb;119(2):421]. J. Clin. Invest. 116, 1955-1962 (2006).
24. Henry, L. R. et al. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin. Cancer Res. 13, 1736-1741 (2007).
25. Scott, A. M. et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res. 9, 1639-1647 (2003).
26. Muris, J. J. et al. Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas. Leukemia 18, 589-596, doi: 10.1038/sj.leu.2403240 (2004).
27. Johnsen, A., France, J., Sy, M. S. & Harding, C. V. Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines. Cancer Res. 58, 3660-3667 (1998).
28. Lee, J., Fassnacht, M., Nair, S., Boczkowski, D. & Gilboa, E. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. Cancer Res. 65, 11156-11163, doi: Doi 10.1158/0008-5472.Can-05-2805 (2005)
29. OBrien, P. & OConnor, B. F. Seprase: an overview of an important matrix serine protease. Biochim. Biophys. Acta 1784, 1130-1145, doi: 10.1016/j.bbapap.2008.01.006 (2008).
30. Liao, D., Luo, Y., Markowitz, D., Xiang, R. & Reisfeld, R. A. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS ONE [Electronic Resource] 4, e7965 (2009).
31. Brennen, W. N., Isaacs, J. T. & Denmeade, S. R. Rationale behind targeting fibroblast activation protein-expressing carcinomaassociated fibroblasts as a novel chemotherapeutic strategy. Mol. Cancer Ther. 11, 257-266, doi: 10.1158/1535-7163.MCT-11-0340 (2012).
32. Hale, M. D., Hayden, J. D. & Grabsch, H. I. Tumour-microenvironment interactions: role of tumour stroma and proteins produced by cancer-associated fibroblasts in chemotherapy response. Cell. Oncol. (Dordr.) 36, 95-112, doi: 10.1007/s13402-013- 0127-7 (2013).
33. Wen, Y. et al. Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model. Cancer Sci. 101, 2325-2332, doi: 10.1111/j.1349-7006.2010.01695.x (2010).
34. Moret-Tatay, I., Diaz, J., Marco, F. M., Crespo, A. & Alino, S. F. Complete tumor prevention by engineered tumor cell vaccines employing nonviral vectors. Cancer Gene Ther. 10, 887-897, doi: 10.1038/sj.cgt.7700646 (2003).
35. Zhao, B. et al. Placenta-derived gp96 as a multivalent prophylactic cancer vaccine. Sci. Rep. 3, 1947, doi: 10.1038/srep01947 (2013).
36. Flemming, A. Cancer: steps towards a prophylactic breast cancer vaccine. Nat Rev Drug Discov 9, 594, doi: 10.1038/nrd3233 (2010).
37. Ostman, A. & Augsten, M. Cancer-associated fibroblasts and tumor growth-bystanders turning into key players. Curr. Opin. Genet. Dev. 19, 67-73, doi: 10.1016/j.gde.2009.01.003 (2009).
38. Schreiber, H. & Rowley, D. A. Cancer. Awakening immunity. Science 330, 761-762, doi: 10.1126/science.1198345 (2010).
39. Liao, D., Luo, Y., Markowitz, D., Xiang, R. & Reisfeld, R. A. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One 4, e7965, doi: 10.1371/ journal.pone.0007965 (2009).
40. Fassnacht, M. et al. Induction of CD4(+ ) and CD8(+ ) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy. Clin. Cancer Res. 11, 5566-5571, doi: 10.1158/1078-0432.CCR-05-0699 (2005).
41. Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. Nature 454, 436-444, doi: 10.1038/nature07205 (2008).
42. Burnett, G. T., Weathersby, D. C., Taylor, T. E. & Bremner, T. A. Regulation of inflammation- and angiogenesis-related gene expression in breast cancer cells and co-cultured macrophages. Anticancer Res. 28, 2093-2099 (2008).
43. Fu, Z. et al. The crosstalk: Tumor-infiltrating lymphocytes rich in regulatory T cells suppressed cancer-associated fibroblasts. Acta Oncol. doi: 10.3109/0284186X.2012.760847 (2013).
44. Gabrilovich, D. I. & Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162-174, doi: 10.1038/nri2506 (2009).
45. Marabelle, A. et al. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J. Clin. Invest. 123, 2447-2463, doi: 10.1172/jci64859 (2013).
46. Luo, Y. et al. Immunotherapy of tumors with protein vaccine based on chicken homologous Tie. Clin. Cancer Res. 12, 1813-1819, doi: 10.1158/1078-0432.CCR-05-1990 (2006).
47. Wang, Y. S. et al. Immunity against tumor angiogenesis induced by a fusion vaccine with murine beta-defensin 2 and mFlk-1. Clin. Cancer Res. 13, 6779-6787, doi: 10.1158/1078-0432.CCR-07-1587 (2007).
48. Liu, J. Y. et al. Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood 102, 1815-1823, doi: 10.1182/blood-2002-12-3772 (2003).
49. Li, D. et al. Gene therapy with beta-defensin 2 induces antitumor immunity and enhances local antitumor effects. Hum. Gene Ther. 25, 63-72, doi: 10.1089/hum.2013.161 (2014).
50. Yuan, W. et al. Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model. Cancer Sci. 101, 2325-2332, doi: 10.1111/j.1349-7006.2010.01695.x (2010).
51. Curtis, C. D., Thorngren, D. L. & Nardulli, A. M. Immunohistochemical analysis of oxidative stress and DNA repair proteins in normal mammary and breast cancer tissues. BMC Cancer 10, 9, doi: 10.1186/1471-2407-10-9 (2010).